摘要
目的:对78例精原细胞瘤患者的治疗结果及其预后因素加以分析。方法:1983年7月至1992年4月收治78例睾丸精原细胞瘤,均经病理证实为纯精原细胞瘤,78例中74例手术治疗,63例术后放疗,43例联合化疗。结果:中位随访6.6年(随访期5～10年),根据《现代肿瘤学》的分期标准,Ⅰ期44例,Ⅱ期21例,Ⅲ期3例,Ⅳ期10例。全组5、10年生存率分别为:Ⅰ期93.2%、87.0%,Ⅱ期66.7%、60.0%,Ⅲ期33.3%,33.3%,Ⅳ期0、0。结论:临床分期、放疗剂量及联合化疗是影响预后的重要因素。强调高位精索加睾丸切除术及术后预防放疗DT2500cGy为Ⅰ期患者首选治疗方案,Ⅱ期以上患者应术后放疗加联合化疗。
Objective:Testicular seminoma is a model for a curable neoplasm.We review past accomplishments and analyse prognosis factors.Methods:During the period from July1983to April1992,78patients aged9to77years old were treated in our hospital,All of them were confirmed by pathology.There were44stageⅠ,21stageⅡ,3stageⅢ,10stageⅣ.74patients were treated by surgery,63patients were treated by postoperative radiotherapy,43patients were treated by combined chemotherapy.Results:With a median follow up6.6years(range5to10).Overal5-year and10-year survival rates were93.2%,87.0%(stageⅠ).66.7%,60.0%(stageⅡ)33.3%,33.3%(stageⅢ).0,0.(stageⅣ),respectively.Conclusion:We identified stage of the primary tumor,dose of radiotherapy and combined chemotherapy as important prognostic factor,and em-phasize that surgery and postoperative radiotherapy will be the first choice for patients of stageⅠ,and patients of stageⅡand above should be treated by postoperative radiotherapy combined chemotherapy.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2003年第3期203-205,共3页
Chinese Journal of Clinical Oncology
